Response to Pederson et al. and Chlebowski et al

Affiliations

¹ Department of Oncology, Odense University Hospital, Odense, Denmark.
² Danish Breast Cancer Group, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
³ Department of Clinical Epidemiology, Clinical Institute, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
⁴ Department of Plastic and Breast Surgery, Aarhus University Hospital, Aarhus, Denmark.
⁵ Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Comment

Søren Cold et al. J Natl Cancer Inst. 2023.

. 2023 Feb 8;115(2):229-230.

doi: 10.1093/jnci/djac214.

¹ Department of Oncology, Odense University Hospital, Odense, Denmark.
² Danish Breast Cancer Group, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
³ Department of Clinical Epidemiology, Clinical Institute, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
⁴ Department of Plastic and Breast Surgery, Aarhus University Hospital, Aarhus, Denmark.
⁵ Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

No abstract available

Comment on

RE: Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study.
Pederson HJ, Faubion SS, Pruthi S, Goldfarb S. Pederson HJ, et al. J Natl Cancer Inst. 2023 Feb 8;115(2):220-221. doi: 10.1093/jnci/djac211. J Natl Cancer Inst. 2023. PMID: 36409007 Free PMC article. No abstract available.
RE: Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study.
Chlebowski RT, Aragaki AK, Pan K. Chlebowski RT, et al. J Natl Cancer Inst. 2023 Feb 8;115(2):222-223. doi: 10.1093/jnci/djac213. J Natl Cancer Inst. 2023. PMID: 36409032 Free PMC article. No abstract available.

1. Pederson HJ, Faubion SS, Pruthi S, Goldfarb S.. RE: systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study. J Natl Cancer Inst. 2022; doi: 10.1093/jnci/djac211. - DOI - PMC - PubMed
1. Chlebowski RT, Aragaki AK, Pan K.. RE: Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study. J Natl Cancer Inst. 2022; doi: 10.1093/jnci/djac213. - DOI - PMC - PubMed
1. Lænkholm AV, Jensen MB, Eriksen JO, et al. PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive Danish cohort of postmenopausal women allocated to 5 years of endocrine therapy for hormone receptor-positive early breast cancer. J Clin Oncol. 2018;36(8):735-740. - PubMed
1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341-1352. - PubMed
1. Christiansen P, Ejlertsen B, Jensen MB, et al. Danish breast cancer cooperative group. Clin Epidemiol. 2016;8:445-449. - PMC - PubMed